Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.360 GeneticVariation disease BEFREE The genetic analysis with whole-exome sequencing studies showed no differential mutations of CTNNB1 (β-catenin) and BRAF (V600E) between TC and NC subtypes, but there was a difference between adamantinomatous craniopharyngioma and papillary craniopharyngioma. 31200374 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.360 GeneticVariation disease BEFREE BRAF V600E and CTNNB1 in papCP and adaCP samples were sequenced by next-generation sequencing and the Sanger method, and mRNA expression levels of Axin2 and BMP4 were evaluated by RT-PCR. 30074466 2018
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.360 GeneticVariation disease BEFREE Frequent somatic mutations of BRAF and CTNNB1 were identified in both histological subtypes of craniopharyngioma (adamantinomatous and papillary) which shed light on target therapy to cure this oncogenic disease. 30616515 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.360 GeneticVariation disease BEFREE The authors have previously shown high mutation rates of BRAF V600E in papillary craniopharyngioma and of CTNNB1 in adamantinomatous craniopharyngioma. 27903124 2016
Entrez Id: 4706
Gene Symbol: NDUFAB1
NDUFAB1
0.040 Biomarker disease BEFREE In the absence of FXN, the NFS1-ISD11-ACP (SDA) complex was reportedly inhibited by binding of recombinant ISCU. 30031876 2018
Entrez Id: 4706
Gene Symbol: NDUFAB1
NDUFAB1
0.040 AlteredExpression disease BEFREE Observed crowding effects on Mycobacterium tuberculosis 2-trans-enoyl-ACP (CoA) reductase enzyme activity are not due to excluded volume only. 28754992 2017
Entrez Id: 4706
Gene Symbol: NDUFAB1
NDUFAB1
0.040 Biomarker disease BEFREE Slow-onset inhibition of 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis by an inorganic complex. 16842188 2006
Entrez Id: 60502
Gene Symbol: CPAT1
CPAT1
0.040 AlteredExpression disease BEFREE Observed crowding effects on Mycobacterium tuberculosis 2-trans-enoyl-ACP (CoA) reductase enzyme activity are not due to excluded volume only. 28754992 2017
Entrez Id: 60502
Gene Symbol: CPAT1
CPAT1
0.040 Biomarker disease BEFREE Slow-onset inhibition of 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis by an inorganic complex. 16842188 2006
Entrez Id: 60502
Gene Symbol: CPAT1
CPAT1
0.040 Biomarker disease BEFREE In the absence of FXN, the NFS1-ISD11-ACP (SDA) complex was reportedly inhibited by binding of recombinant ISCU. 30031876 2018
Entrez Id: 4706
Gene Symbol: NDUFAB1
NDUFAB1
0.040 Biomarker disease BEFREE In this study, we have investigated the influence of the quaternary structure of 2-trans-enoyl-ACP (CoA) reductase or InhA, from Mycobacterium tuberculosis, to its flexibility. 31548581 2019
Entrez Id: 60502
Gene Symbol: CPAT1
CPAT1
0.040 Biomarker disease BEFREE In this study, we have investigated the influence of the quaternary structure of 2-trans-enoyl-ACP (CoA) reductase or InhA, from Mycobacterium tuberculosis, to its flexibility. 31548581 2019
Entrez Id: 3569
Gene Symbol: IL6
IL6
0.030 AlteredExpression disease BEFREE Significantly increased levels of IL-6 and IL-10 were found in ACP compared with control. 31249603 2019
Entrez Id: 3569
Gene Symbol: IL6
IL6
0.030 Biomarker disease BEFREE While there is evidence to suggest that interleukin‑6 (IL‑6) induces craniopharyngioma (CP)‑associated inflammation, particularly in ACP, the role of IL‑6 in the progression of ACP remains unclear. 28487953 2017
Entrez Id: 3569
Gene Symbol: IL6
IL6
0.030 Biomarker disease BEFREE Cytokines and chemokines with particularly elevated concentrations in ACPs were IL-6, CXCL1 (GRO), CXCL8 (IL-8) and the immunosuppressive cytokine IL-10. 28859336 2017
Entrez Id: 7080
Gene Symbol: NKX2-1
NKX2-1
0.010 Biomarker disease BEFREE In this review, we outline six major areas of advances: (i) changes in terminology from 'adenoma' to 'pituitary neuroendocrine tumour'; (ii) reclassification of hormone-negative tumours based on transcription factor expression that defines lineage; (iii) updates in new pathogenetic mechanisms, including those that underlie rare lesions such as X-LAG and pituitary blastoma; (iv) clarification of hypophysitis due to immunotherapy, xanthomatous hypophysitis due to rupture of a Rathke's cleft cyst and IgG4 disease as the cause of inflammatory pseudotumour; (v) the consolidation of pituicytoma variants, including spindle cell oncocytoma and granular cell tumour based on thyroid transcription factor-1 (TTF-1) reactivity; and (vi) the pathogenetic mechanisms that distinguish papillary from adamantinomatous craniopharyngioma. 29239033 2018
Entrez Id: 3552
Gene Symbol: IL1A
IL1A
0.010 Biomarker disease BEFREE Interleukin-1α leads to growth hormone deficiency in adamantinomatous craniopharyngioma by targeting pericytes: implication in pituitary fibrosis. 31666193 2019
Entrez Id: 2688
Gene Symbol: GH1
GH1
0.010 Biomarker disease BEFREE To diagnosis of GHD, the Body Mass Index (BMI), Insulin Like Growth Factor-1(IGF-1) and peak growth hormone (GH) values after insulin stimulation test of 15 aCP patients were recorded. 31666193 2019
Entrez Id: 2247
Gene Symbol: FGF2
FGF2
0.010 AlteredExpression disease BEFREE The expression of basic fibroblast growth factor and transforming growth factor beta was significantly higher in ACPs than in chronic rhinosinusitis and healthy mucosa. 16955781 2006
Entrez Id: 1356
Gene Symbol: CP
CP
0.010 Biomarker disease BEFREE Ceruloplasmin, a multi-copper oxidase, is mainly involved in iron metabolism and its genetic defect, aceruloplasminemia (ACP), shows neurological disorders and diabetes associated with excessive iron accumulation, but little is known about the state of copper in the brain. 27272717 2017
Entrez Id: 10631
Gene Symbol: POSTN
POSTN
0.010 AlteredExpression disease BEFREE It was found that POSTN expression increased in ACP-associated fibroblasts. 26723972 2016
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.010 AlteredExpression disease BEFREE We mapped and quantified PD-L1 and PD-1 expression in ACP and PCP resections using immunohistochemistry, immunofluorescence, and RNA in situ hybridization. 29509940 2018
Entrez Id: 1080
Gene Symbol: CFTR
CFTR
0.010 GeneticVariation disease BEFREE Three mutations of CFTR were detected in four ACP patients with a prevalence (8.9%) not significantly different from that observed (3.0%) in ALD patients and from that expected (3.2%) in our geographical area. 12939655 2003
Entrez Id: 1571
Gene Symbol: CYP2E1
CYP2E1
0.010 AlteredExpression disease BEFREE Significant increases in CYP2E1 mRNA and protein expression were observed in freshly prepared blood lymphocytes isolated from ACs and ACP patients as compared with respective NACs or NACP patients. 20843640 2011
Entrez Id: 302
Gene Symbol: ANXA2
ANXA2
0.010 AlteredExpression disease BEFREE Immunohistochemistry assays indicated the expression level of AnxA2 was significantly higher in recurrent AdaCPs compared with primary ones. 27640198 2017